PP405 (suvomipic): status, and when it could arrive

What is PP405?

PP405 is a topical experimental treatment intended to wake dormant hair follicle stem cells by changing their metabolism. It is not approved for hair loss as of October 2026.

The mechanism takes hold in an unusual place: the cell's energy metabolism. PP405 slows a transporter called MPC (mitochondrial pyruvate carrier), and the idea is that this pushes a dormant hair follicle back into activity — a follicle that is still there but no longer produces visible hair. It is a different approach from the approved treatments: finasteride lowers DHT, minoxidil stimulates growth, while PP405 tries to restart the hair follicle itself. The treatment is being developed by the company Pelage and grew out of research from UCLA.

Does PP405 work — do you get your hair back?

That has not been established. A phase 2 trial showed that the treatment was tolerable and was not absorbed to any notable extent into the body, but the actual effect on hair growth has not yet been documented in a large trial.

Here it is important to distinguish between mechanism and proven effect. The mechanism (waking stem cells) is promising in the laboratory, but a small, early trial focused on safety is not the same as documented hair growth. The figures you may come across online (for example “31%”) come from such a small, early trial and reflect an early signal of stem cell activation, not a measurement of hair density or restored hair. They should therefore not be read as evidence that the treatment gets your hair back. The decisive evidence must come from the larger trial now under way.

When could PP405 reach the market?

That is unknown, and all dates are uncertain. A larger phase 2/3 trial began dosing participants in autumn 2026, and even in the best case the treatment must both show effect and clear a regulatory approval before it can be prescribed.

The years you see elsewhere (for example “2028”) are at best educated guesses, not promises. An approval in Denmark and the EU typically comes after an approval in the US. We update the status here when new, documented results arrive. See the full overview in our guide to new hair loss treatments.

Is PP405 the same as suvomipic or JXL069?

PP405 carries the proposed common name suvomipic. You will also see it linked to a research substance called JXL069, but that link rests on a few sources and has not been clearly confirmed by the developer. We therefore present it as a claim, not as a fact.

Naming confusion is common with experimental treatments. Whatever the name, the treatment is not approved and not for sale for hair loss, and that does not change what the trials have shown.

Can I buy PP405 now?

No. PP405 is not approved for hair loss and cannot legally be prescribed for that use. Products sold online as “PP405” or “JXL069” are not approved medicine: content, purity and safety are unknown, and some are counterfeits.

Never buy unregulated substances to apply to your scalp. If you want to do something now, stick to what is approved and documented, in consultation with a doctor, and treat the experimental treatments as something you follow, not something you obtain.

Sources

1. Flores A, Schell J, Krall AS, et al. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nature Cell Biology, 2017;19(9):1017-1026. pubmed.ncbi.nlm.nih.gov/28812580
2. ClinicalTrials.gov. Safety, Pharmacokinetics and Efficacy of PP405 in Adults With Androgenetic Alopecia (phase 2, completed). NCT06393452. clinicaltrials.gov/study/NCT06393452
3. ClinicalTrials.gov. Phase 2/3 Efficacy and Safety of PP405 in Adult Males With Androgenetic Alopecia (phase 2/3, recruiting; dosing began September 2026). NCT07819435. clinicaltrials.gov/study/NCT07819435

This article summarises published research. It is general educational information, not medical advice, and it is not a recommendation to start, stop or change any medication. Prescription drugs carry contraindications and interactions; discuss them with a doctor who knows your medical history.